Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Luci vs NuuVim

Luci
Graded #99

Higher grade

vs+2.799999999999997
NuuVim
Graded #153

Lower grade

The verdict

Luci takes it — 71/100 to 68.2/100.

Luci grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Luci is a budget-focused GLP-1 telehealth platform offering compounded medications with upfront pricing: compounded semaglutide as low as $99/month and compounded tirzepatide as low as $145/month, plus oral…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +4
84
88
Dose & formulationNuuVim +21
75
96
Clinical oversightLuci +29
71
42
Labs & monitoringLuci +3
53
50
FulfillmentLuci +9
70
61
Contract termsLuci +8
55
47
Luci · left barNuuVim · right bar

The numbers

MetricLuciNuuVim
WeighScore71/10068.2/100
GradeCC
Scorecard rank#99#153
Semaglutide$99/mo (starting dose, promotional rate, compounded)$79/mo (all doses, 3-mo plan, new patients only, compounded)
Tirzepatide$145/mo (starting dose, promotional rate, compounded)$133/mo (all doses, 3-mo plan, new patients only, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Luci

Graded #99 · C

Strengths

  • Budget-friendly compounded GLP-1 pricing (compounded semaglutide as low as $99/month, tirzepatide as low as $145/month)
  • Multiple formats: compounded semaglutide and tirzepatide injections plus oral semaglutide and tirzepatide pill kits
  • Upfront pricing with no insurance required and a fast 3-minute questionnaire to start
  • Care delivered through DrTelx, an independent US telehealth medical group, with ongoing support and dose optimization
  • HIPAA-compliant platform with a large self-reported member base (50,000+)

Where it loses points

  • Compounded medications are not FDA-approved for weight loss (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Available only in select U.S. states, and the full state list is not published
  • The compounding pharmacy partner is not named
  • Headline prices are 'as low as' rates (asterisked) — your actual monthly cost may be higher
  • No LegitScript certification displayed; marketing leans heavily on testimonials
NuuVim

Graded #153 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • There is no month-to-month plan: every rate is billed as one three-month payment
  • The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
  • The site's own llms.txt advertises pricing, FAQ and terms files that all 404
  • No state count is published
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard